enrollment is ongoing." Bispecific Clinical Combination therapy First-in-human P1/2 data Carcinosarcoma Dry Eye Disease Endometrial Cancer Oncology Ophthalmology Ovarian Cancer Sarcoma Solid Tumor MUC16 April 24, 2026 Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies
and GHRP-2 (Growth Hormone Releasing Peptide-2), a potent hexapeptide with well-characterized effects on both pituitary and hypothalamic GH release pathways
For glucose control, head-to-head trials have shown that oral semaglutide 14mg produces HbA1c reductions comparable to the injectable form at lower doses, making it a clinically meaningful option for many patients with type 2 diabetes whose primary goal is glucose management with cardiovascular protection
Further evaluation in patients with NAFLD/NASH is warranted, with outcome measures such as steatosis or inflammation reduction
Eur J Med Res 31 , 961 (2026)
